Lv2
150 积分 2024-10-11 加入
A highly selective and potent TLR8 agonist ZG0895 in preclinical studies of anti-tumor activities
1个月前
已关闭
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression
1个月前
已完结
Tumor‐Selective Activation of Toll‐Like Receptor 7/8 Agonist Nano‐Immunomodulator Generates Safe Anti‐Tumor Immune Responses upon Systemic Administration
1个月前
已完结
Immune Modulating Antibody–Drug Conjugate (IM-ADC) for Cancer Immunotherapy
1个月前
已完结
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
1个月前
已完结
皖公网安备34019202002308
